
Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.

Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.

A recent study identified a significant association between psoriasis and inflammatory bowel disease. This link also applied to IBD subtypes: Crohn disease and ulcerative colitis.

The systemic immune-inflammation index (SII) was found to be a potential predictor of the prognosis of patients with chronic obstructive pulmonary disease (COPD).

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

This week's news from the Center on Health Equity and Access discusses racial disparities in prostate cancer outcomes, the impact of access to cancer care on racial gaps in CLL/SLL outcomes, the effects of 340B programs on drug pricing and health care disparities, the role of mental illness in maternal mortality rates, and racial bias and diagnosis disparities in bipolar disorder.

Patients with ovarian cancer living in rural areas reported less improvement in psychological function compared with patients living in urban areas in the year following ovarian cancer diagnosis.

Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.

Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.

The House Democratic Women’s Caucus wrote a letter urging insurers to comply with both contraceptive coverage requirements and recent Biden administration guidance; several pharmacy chains are experiencing disruptions following a hack at Change Healthcare, UnitedHealth’s technology unit; the FDA said it is not planning to take a tougher stance against clinical trial reporting requirement noncompliance.

In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.

In honor of Black History Month, Leesha Ellis-Cox, MD, MPH, sheds light on the racial disparities in mental health care and the prevalence of misdiagnosis.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

This study was the first of its kind to explore how taking statin medication affects blood vessel function and exercise response in patients with heart failure with preserved ejection fraction (HFpEF), although the cohort only included 16 patients.

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Glaucoma specialists were outperformed by a large language model chatbot when it came to diagnostic and treatment accuracy in glaucoma cases.

Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.

Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures.

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.

A review found that CD4/CD8 ratio could be used as a prognostic marker for mortality in patients with HIV, though future studies need to be done to confirm these findings.

More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.

A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.

For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.

Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.

Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.

Strengthening parity in insurance coverage of mental and physical health care benefits is critical for addressing the maternal mental health crisis.

Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
